Developer docs
API playgroundTry for free, no card

Search company profiles

OMEICOS Therapeutics

Full company profile

uuid0002cx6

Namestring
OMEICOS Therapeutics
Legal namestring
OMEICOS Therapeutics GmbH
Websiteurl
omeicos.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

OMEICOS Therapeutics GmbH is a privately held, clinical-stage biopharmaceutical company founded in June 2013 as a spin-off of the Max Delbrück Center for Molecular Medicine (MDC) in Berlin. The company develops first-in-class, orally available small molecule therapeutics based on metabolically stable synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids (17,18-EEQ). Its lead compound, OMT-28, targets the GPCR receptor S1PR1 to drive downstream activation of the mitochondrial sirtuins SIRT1 and SIRT3 within the AMPK/SIRT1/SIRT3/PGC1-alpha network, combining immunomodulation with mitochondrial protection — a dual mechanism differentiating OMT-28 from single-mechanism competitors.

The company's pipeline is oriented toward diseases of high unmet medical need: Primary Mitochondrial Disease (PMD), atrial fibrillation (AF), cardiovascular inflammation/Coronary Artery Disease, and ophthalmological disorders (wet AMD, diabetic retinopathy). OMT-28 has been evaluated in more than 220 individuals across Phase 1, Phase 2, and the PMD-OPTION study, with a positive Phase 2a PMD-OPTION readout announced in January 2026 and a potentially pivotal Phase 2b/3 study planned for H2 2026. Operations span Germany (Berlin headquarters), the United States (wholly-owned subsidiary OMEICOS Ophthalmics, Inc. in Cambridge, MA), and clinical trial sites in Italy and the Netherlands.

OMEICOS' business model is asset-development-driven and pre-revenue: the company finances operations through successive venture equity rounds (cumulative approximately EUR 40 million led by Vesalius Biocapital, Forbion, and Remiges) supplemented by non-dilutive grants (approximately EUR 6.5 million from BMBF and Investitionsbank Berlin). With 11–50 employees and no commercialized product, the company is explicitly preparing for late-stage development and commercialization through partnering or licensing transactions rather than building an in-house commercial organization.

Short descriptiontext

OMEICOS Therapeutics is a Berlin-based, clinical-stage biopharmaceutical company developing orally available small molecule therapeutics (lead asset OMT-28) that activate S1PR1/SIRT1/SIRT3 pathways to treat primary mitochondrial disease, atrial fibrillation, cardiovascular inflammation, and ophthalmological disorders.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBerlin, Germany
HQ citystring
Berlin
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule therapeutics, clinical-stage biopharmaceuticals, mitochondrial disease treatment, cardiovascular drug development, epoxyeicosanoid analogues
Industry1 code
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Cardiovascular and Mitochondrial Disease Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Development and Commercialization
TypeOne Time License
Description

OMEICOS is a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics for mitochondrial and inflammatory disorders. The company is advancing OMT-28 through clinical trials toward potential approval and commercialization. Current focus is on completing Phase 2b/3 development in Primary Mitochondrial Disease and exploring partnering opportunities for late-stage development.

omeicos.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

OMEICOS Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class, orally available small molecule therapeutics (lead compound OMT-28) based on metabolically stable synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids. The lead candidate targets the S1PR1 receptor and activates mitochondrial sirtuins SIRT1/SIRT3, addressing Primary Mitochondrial Disease, atrial fibrillation, cardiovascular inflammation, and ophthalmological disorders. The company currently generates no product revenue, operating via equity financing and non-dilutive grants while preparing for late-stage clinical development and potential partnering.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Over 60% response rate in PMD-OPTION study patients
+5 more records
Product overview1 text field

OMEICOS Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics based on synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids. The company's core product is lead compound OMT-28, currently in Phase 2 clinical development for Primary Mitochondrial Disease and previously evaluated in atrial fibrillation. OMT-28 targets the GPCR receptor S1PR1 to activate the AMPK/SIRT1/SIRT3/PGC1-alpha axis, combining immunomodulation with mitochondrial protection. The company's proprietary compound library supports multiple therapeutic programs including cardiovascular, inflammatory, mitochondrial, and ophthalmological diseases. OMT-28 has demonstrated excellent safety across over 220 individuals and shown significant positive effects on inflammatory biomarkers (GDF-15, IL-6) and mitochondrial function.

Product and service3 records
1OMT-28
CategoryCore clinical-stage drug candidate
Description

A first-in-class, orally available, once-daily small molecule therapeutic; a metabolically stable synthetic analog of the omega-3 fatty acid metabolite 17,18-EEQ. It is a biased modulator of GPCR receptor S1PR1 that drives downstream activation of mitochondrial sirtuins SIRT1 and SIRT3, combining immunomodulation with mitochondrial protection for the treatment of Primary Mitochondrial Disease (PMD), atrial fibrillation, and cardiovascular inflammation. Safety/tolerability has been evaluated in 220+ individuals with demonstrated biomarker effects on NAD+/NADH, GSH/GSSG, GDF-15, and IL-6.

2OMEICOS Compound Library
CategoryProprietary drug discovery platform
Description

A proprietary library of metabolically robust, orally available synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids developed using industry-leading knowledge of omega-3 fatty acid metabolism and biology. The library underpins OMEICOS' pipeline across cardiovascular, inflammatory, mitochondrial, and ophthalmological diseases and supports multiple therapeutic programs beyond OMT-28.

3OMT-28 for Ophthalmology
CategorySub-program (ophthalmology indication)
Description

Exploratory development of OMT-28 for severe ophthalmological disorders including wet age-related macular degeneration (wet AMD) and diabetic retinopathy. Oral administration has demonstrated comparable therapeutic effects to intravitreally applied anti-VEGF therapy in preclinical mouse models in reducing abnormal blood vessel formation and leakiness. Being advanced via the US subsidiary OMEICOS Ophthalmics, Inc.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2019-04-29
Description

Berlin-based medical device specialist providing implantable cardiac monitors for the PROMISE-AF clinical study to accurately detect and monitor arrhythmias and assess AF burden in patients.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-03-01
Description

Collaboration with Prof. John R. Falck who pioneered identification and chemical synthesis of CYP eicosanoids. Falck is Welch Distinguished Chair of Chemistry at UT Southwestern.

3Max Delbrück Center for Molecular Medicine (MDC)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2013-06-01
Description

OMI ECOS was spun out of MDC in Berlin in June 2013 based on ground-breaking discoveries in omega-3 fatty acid metabolism by founders including Dr. Wolf-Hagen Schunck. Ongoing collaboration for research and clinical activities.

omeicos.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Stealth BioTherapeutics
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing mitochondrial-targeted therapeutics, including elamipretide for primary mitochondrial disease and Barth syndrome. Directly comparable to OMEICOS in target indication (PMD) and mechanistic focus on mitochondrial bioenergetics.

TypeDirect peer
Description

Netherlands-based clinical-stage company developing small-molecule mitochondrial therapeutics, with lead asset sonlicromanol in Phase 2b for mitochondrial disease. Closely comparable in indication, modality (small molecule), and stage to OMEICOS' OMT-28.

TypeDirect peer
Description

Sweden-based mitochondrial medicine company developing KL1333 and other compounds for primary mitochondrial disease. Comparable in indication, small-molecule modality, and clinical-stage development profile.

TypeDirect peer
Description

Clinical-stage company developing mavodelpar (REN001) for primary mitochondrial myopathies and other mitochondrial disorders. Closely comparable in indication (PMD myopathy), small-molecule modality, and clinical-stage development.

TypeDirect peer
Description

Clinical-stage company developing an inhaled flecainide formulation for paroxysmal atrial fibrillation. Directly comparable to OMEICOS' previous AF development focus with OMT-28, though differentiated by route of administration.

TypeEmerging player
Description

Boston-based cardiovascular drug development company advancing therapies for heart failure, arrhythmias, and other cardiovascular diseases. Comparable in CV therapeutic focus, particularly overlapping with OMEICOS' atrial fibrillation and cardiovascular inflammation programs.

TypeBroad incumbent
Description

Established commercial-stage rare disease company with multiple approved products for genetic and orphan disorders. Comparable as a larger rare disease specialty pharma, providing relevant M&A and partnership comparables for OMEICOS' orphan PMD strategy.

TypeBroad incumbent
Description

Major rare disease biopharmaceutical company with a portfolio of approved enzyme replacement and gene therapies for ultra-rare conditions. Relevant comparable for orphan disease pricing, regulatory strategy, and M&A benchmark for OMEICOS.

TypeBroad incumbent
Description

Market leader in wet AMD through Lucentis and Susvimo, and developer of Vabysmo. Relevant comparable as the dominant incumbent in the ophthalmology indication OMEICOS is targeting with its oral anti-VEGF alternative approach.

TypeBroad incumbent
Description

Developer of Eylea (aflibercept), the market-leading anti-VEGF therapy for wet AMD and diabetic retinopathy. Directly comparable as the incumbent standard-of-care that OMEICOS' oral ophthalmology program would aim to disrupt.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OMEICOS Therapeutics

Cardiovascular and Mitochondrial Disease Therapeuticsomeicos.com

OMEICOS Therapeutics is a Berlin-based, clinical-stage biopharmaceutical company developing orally available small molecule therapeutics (lead asset OMT-28) that activate S1PR1/SIRT1/SIRT3 pathways to treat primary mitochondrial disease, atrial fibrillation, cardiovascular inflammation, and ophthalmological disorders.

What OMEICOS Therapeutics does

OMEICOS Therapeutics GmbH is a privately held, clinical-stage biopharmaceutical company founded in June 2013 as a spin-off of the Max Delbrück Center for Molecular Medicine (MDC) in Berlin. The company develops first-in-class, orally available small molecule therapeutics based on metabolically stable synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids (17,18-EEQ). Its lead compound, OMT-28, targets the GPCR receptor S1PR1 to drive downstream activation of the mitochondrial sirtuins SIRT1 and SIRT3 within the AMPK/SIRT1/SIRT3/PGC1-alpha network, combining immunomodulation with mitochondrial protection — a dual mechanism differentiating OMT-28 from single-mechanism competitors.

The company's pipeline is oriented toward diseases of high unmet medical need: Primary Mitochondrial Disease (PMD), atrial fibrillation (AF), cardiovascular inflammation/Coronary Artery Disease, and ophthalmological disorders (wet AMD, diabetic retinopathy). OMT-28 has been evaluated in more than 220 individuals across Phase 1, Phase 2, and the PMD-OPTION study, with a positive Phase 2a PMD-OPTION readout announced in January 2026 and a potentially pivotal Phase 2b/3 study planned for H2 2026. Operations span Germany (Berlin headquarters), the United States (wholly-owned subsidiary OMEICOS Ophthalmics, Inc. in Cambridge, MA), and clinical trial sites in Italy and the Netherlands.

OMEICOS' business model is asset-development-driven and pre-revenue: the company finances operations through successive venture equity rounds (cumulative approximately EUR 40 million led by Vesalius Biocapital, Forbion, and Remiges) supplemented by non-dilutive grants (approximately EUR 6.5 million from BMBF and Investitionsbank Berlin). With 11–50 employees and no commercialized product, the company is explicitly preparing for late-stage development and commercialization through partnering or licensing transactions rather than building an in-house commercial organization.

OMEICOS Therapeutics firmographics

Firmographics
Name
OMEICOS Therapeutics
Legal name
OMEICOS Therapeutics GmbH
Website
https://omeicos.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
OMEICOS Therapeutics is a Berlin-based, clinical-stage biopharmaceutical company developing orally available small molecule therapeutics (lead asset OMT-28) that activate S1PR1/SIRT1/SIRT3 pathways to treat primary mitochondrial disease, atrial fibrillation, cardiovascular inflammation, and ophthalmological disorders.
Ownership category
akta.pro rank

OMEICOS Therapeutics industry classification

Industry
Product category
Cardiovascular and Mitochondrial Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Small molecule therapeutics
  • Clinical-stage biopharmaceuticals
  • Mitochondrial disease treatment
  • Cardiovascular drug development
  • Epoxyeicosanoid analogues

Where OMEICOS Therapeutics is headquartered

Location

Headquarters

HQ city
Berlin
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

OMEICOS Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Pharmaceutical Drug Development and Commercialization: OMEICOS is a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics for mitochondrial and inflammatory disorders. The company is advancing OMT-28 through clinical trials toward potential approval and commercialization. Current focus is on completing Phase 2b/3 development in Primary Mitochondrial Disease and exploring partnering opportunities for late-stage development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

OMEICOS Therapeutics product offering

Product offering

Core offering

OMEICOS Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class, orally available small molecule therapeutics (lead compound OMT-28) based on metabolically stable synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids. The lead candidate targets the S1PR1 receptor and activates mitochondrial sirtuins SIRT1/SIRT3, addressing Primary Mitochondrial Disease, atrial fibrillation, cardiovascular inflammation, and ophthalmological disorders. The company currently generates no product revenue, operating via equity financing and non-dilutive grants while preparing for late-stage clinical development and potential partnering.

Product overview

OMEICOS Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics based on synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids. The company's core product is lead compound OMT-28, currently in Phase 2 clinical development for Primary Mitochondrial Disease and previously evaluated in atrial fibrillation. OMT-28 targets the GPCR receptor S1PR1 to activate the AMPK/SIRT1/SIRT3/PGC1-alpha axis, combining immunomodulation with mitochondrial protection. The company's proprietary compound library supports multiple therapeutic programs including cardiovascular, inflammatory, mitochondrial, and ophthalmological diseases. OMT-28 has demonstrated excellent safety across over 220 individuals and shown significant positive effects on inflammatory biomarkers (GDF-15, IL-6) and mitochondrial function.

Differentiator

Problem solved

Functional benefit

Products and services

  • OMT-28 A first-in-class, orally available, once-daily small molecule therapeutic; a metabolically stable synthetic analog of the omega-3 fatty acid metabolite 17,18-EEQ. It is a biased modulator of GPCR receptor S1PR1 that drives downstream activation of mitochondrial sirtuins SIRT1 and SIRT3, combining immunomodulation with mitochondrial protection for the treatment of Primary Mitochondrial Disease (PMD), atrial fibrillation, and cardiovascular inflammation. Safety/tolerability has been evaluated in 220+ individuals with demonstrated biomarker effects on NAD+/NADH, GSH/GSSG, GDF-15, and IL-6.
  • OMEICOS Compound Library A proprietary library of metabolically robust, orally available synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids developed using industry-leading knowledge of omega-3 fatty acid metabolism and biology. The library underpins OMEICOS' pipeline across cardiovascular, inflammatory, mitochondrial, and ophthalmological diseases and supports multiple therapeutic programs beyond OMT-28.
  • OMT-28 for Ophthalmology Exploratory development of OMT-28 for severe ophthalmological disorders including wet age-related macular degeneration (wet AMD) and diabetic retinopathy. Oral administration has demonstrated comparable therapeutic effects to intravitreally applied anti-VEGF therapy in preclinical mouse models in reducing abnormal blood vessel formation and leakiness. Being advanced via the US subsidiary OMEICOS Ophthalmics, Inc.

Quantifiable outcome

  • Over 60% response rate in PMD-OPTION study patients
  • +5 more outcomes

Companies that use OMEICOS Therapeutics

Customer profile

Segments4 records

Ideal customer profiles5 records

OMEICOS Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

OMEICOS Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered major and core.

  • BiotronikmajorTechnology or Integration · 29 April 2019Berlin-based medical device specialist providing implantable cardiac monitors for the PROMISE-AF clinical study to accurately detect and monitor arrhythmias and assess AF burden in patients.
  • University of Texas Southwestern Medical CentercoreStrategic or Co-development Partner · 1 March 2017Collaboration with Prof. John R. Falck who pioneered identification and chemical synthesis of CYP eicosanoids. Falck is Welch Distinguished Chair of Chemistry at UT Southwestern.
  • Max Delbrück Center for Molecular Medicine (MDC)coreStrategic or Co-development Partner · 1 June 2013OMI ECOS was spun out of MDC in Berlin in June 2013 based on ground-breaking discoveries in omega-3 fatty acid metabolism by founders including Dr. Wolf-Hagen Schunck. Ongoing collaboration for research and clinical activities.

Scale indicators9 records

Recent moves8 records

Expansion highlights5 records

OMEICOS Therapeutics competitors and assessment

Company assessment

Direct peers

  • Stealth BioTherapeutics: Clinical-stage biopharmaceutical company developing mitochondrial-targeted therapeutics, including elamipretide for primary mitochondrial disease and Barth syndrome. Directly comparable to OMEICOS in target indication (PMD) and mechanistic focus on mitochondrial bioenergetics.
  • Khondrion: Netherlands-based clinical-stage company developing small-molecule mitochondrial therapeutics, with lead asset sonlicromanol in Phase 2b for mitochondrial disease. Closely comparable in indication, modality (small molecule), and stage to OMEICOS' OMT-28.
  • Abliva AB (formerly NeuroVive Pharmaceutical): Sweden-based mitochondrial medicine company developing KL1333 and other compounds for primary mitochondrial disease. Comparable in indication, small-molecule modality, and clinical-stage development profile.
  • Reneo Pharmaceuticals: Clinical-stage company developing mavodelpar (REN001) for primary mitochondrial myopathies and other mitochondrial disorders. Closely comparable in indication (PMD myopathy), small-molecule modality, and clinical-stage development.
  • InCarda Therapeutics: Clinical-stage company developing an inhaled flecainide formulation for paroxysmal atrial fibrillation. Directly comparable to OMEICOS' previous AF development focus with OMT-28, though differentiated by route of administration.

Emerging players

  • Cardurion Pharmaceuticals: Boston-based cardiovascular drug development company advancing therapies for heart failure, arrhythmias, and other cardiovascular diseases. Comparable in CV therapeutic focus, particularly overlapping with OMEICOS' atrial fibrillation and cardiovascular inflammation programs.

Broad incumbents

  • PTC Therapeutics: Established commercial-stage rare disease company with multiple approved products for genetic and orphan disorders. Comparable as a larger rare disease specialty pharma, providing relevant M&A and partnership comparables for OMEICOS' orphan PMD strategy.
  • BioMarin Pharmaceutical: Major rare disease biopharmaceutical company with a portfolio of approved enzyme replacement and gene therapies for ultra-rare conditions. Relevant comparable for orphan disease pricing, regulatory strategy, and M&A benchmark for OMEICOS.
  • Genentech (Roche): Market leader in wet AMD through Lucentis and Susvimo, and developer of Vabysmo. Relevant comparable as the dominant incumbent in the ophthalmology indication OMEICOS is targeting with its oral anti-VEGF alternative approach.
  • Regeneron Pharmaceuticals: Developer of Eylea (aflibercept), the market-leading anti-VEGF therapy for wet AMD and diabetic retinopathy. Directly comparable as the incumbent standard-of-care that OMEICOS' oral ophthalmology program would aim to disrupt.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

OMEICOS Therapeutics social profiles

Digital presence

OMEICOS Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OMEICOS Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

OMEICOS Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

OMEICOS Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OMEICOS Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OMEICOS Therapeutics

What does OMEICOS Therapeutics do?

OMEICOS Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class, orally available small molecule therapeutics (lead compound OMT-28) based on metabolically stable synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids. The lead candidate targets the S1PR1 receptor and activates mitochondrial sirtuins SIRT1/SIRT3, addressing Primary Mitochondrial Disease, atrial fibrillation, cardiovascular inflammation, and ophthalmological disorders. The company currently generates no product revenue, operating via equity financing and non-dilutive grants while preparing for late-stage clinical development and potential partnering.

Is OMEICOS Therapeutics a public or private company?

OMEICOS Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was OMEICOS Therapeutics founded?

OMEICOS Therapeutics was founded in 2013. It employs 1 to 10 people.

Where is OMEICOS Therapeutics based?

OMEICOS Therapeutics is headquartered in Berlin, Germany, in the Europe region.

How does OMEICOS Therapeutics make money?

One revenue line is on record: pharmaceutical Drug Development and Commercialization.

Who are OMEICOS Therapeutics's main competitors?

Direct peers on record are Stealth BioTherapeutics, Khondrion, Abliva AB (formerly NeuroVive Pharmaceutical), Reneo Pharmaceuticals and InCarda Therapeutics. Cardurion Pharmaceuticals is listed as an emerging player. Broad incumbents are PTC Therapeutics, BioMarin Pharmaceutical, Genentech (Roche) and Regeneron Pharmaceuticals.

Does OMEICOS Therapeutics have an API?

No public API is recorded for OMEICOS Therapeutics.

What industry is OMEICOS Therapeutics in?

OMEICOS Therapeutics's product category is Cardiovascular and Mitochondrial Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
European BiotechnologyOMEICOS takes repurposed drug directly into Phase 3OMEICOS Therapeutics received FDA support to move OMT-28 into a Phase 3 trial for primary mitochondrial diseases. The adaptive trial will enroll up to 160 adults, with a primary endpoint combining walking and sit-to-stand tests. The company is now seeking financing and a development partner to launch the study.FinancialContent Business PageOMEICOS’ OMT-28 Headed for Phase 3 in Primary Mitochondrial Diseases (PMD) Following Positive End-of-Phase 2 Meeting with the FDAOMEICOS Therapeutics announced the successful completion of an End-of-Phase 2 meeting with the FDA, receiving strong agency support to advance OMT-28 directly into a pivotal Phase 3 study for Primary Mitochondrial Diseases. The Phase 2a PMD-OPTION Study demonstrated significant recovery of impaired mitochondrial function and confirmed an excellent safety profile across more than 190 individuals evaluated. The company is evaluating strategic partners and resources to support the upcoming trial, which is planned to enroll up to 160 adult patients using an adaptive design over 24 to 104 weeks.BioSpaceOMEICOS’ OMT-28 Headed for Phase 3 in Primary Mitochondrial Diseases (PMD) Following Positive End-of-Phase 2 Meeting with the FDAOMEICOS announced the FDA's positive End-of-Phase 2 meeting for OMT-28, supporting its direct advancement to a pivotal Phase 3 study in Primary Mitochondrial Diseases. The Phase 3 trial will enroll up to 160 adult patients, evaluating efficacy at a 24 mg once-daily dose over 24 weeks. The company aims to bring the therapy to medical practice as quickly as possible.Labiotech.euSix biotech companies in Berlin to watch in 2026This article profiles six biotech companies in Berlin, Germany, highlighting their recent developments and innovations across oncology, regenerative therapies, and mitochondrial dysfunction treatments. The companies profiled include 3B Pharmaceuticals (which partnered with TetraKit Technologies and licensed technology to Novartis), Ariceum Therapeutics (dosed first patient in phase 1/2 study), Captain T Cell (secured €20M funding), MyoPax (selected for BIO-Europe and received €2.5M grant), OMEICOS Therapeutics (concluded successful phase 2a study), and T-knife Therapeutics (received CTA authorization for phase 1 study). Berlin's biotech ecosystem comprises approximately 300 companies with 8,200 employees, with nearly 80% focused on developing innovative therapeutic and diagnostic methods.GlobeNewswireOMEICOS Therapeutics Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial DiseaseOMEICOS completed enrollment in its Phase 2a PMD-OPTION study of OMT-28 in 28 primary mitochondrial disease patients. Interim data shows a strong safety profile and promising GDF-15 reduction, with top-line data expected mid-2025.FinSMEsOmeicos Therapeutics Raises €17M in Series C FinancingOmeicos Therapeutics raised €17M in Series C financing led by Forbion, with participation from existing investors. The company's lead compound OMT-28 met its primary endpoint in a Phase I study for atrial fibrillation, and the funds will finance a Phase II trial. Holger Reithinger will join the board.FinSMEsOmeicos Announces First Closing of €8.3M Series B FinancingOmeicos Therapeutics closed its first €8.3M Series B financing, led by Vesalius Biocapital II, SICAR, and SMS Company Group. The funds will support a Phase 1 clinical trial of OMT-28 for atrial fibrillation. The company, a Berlin spin-off, is developing omega-3-derived small molecules for cardiovascular diseases.FinSMEsOmeicos Therapeutics Raises €6.2M in Series A FundingOmeicos Therapeutics, a Berlin-based biopharmaceutical company, raised €6.2M in a Series A round led by Vesalius Biocapital II, with participation from SMS Group, VC Fonds Technologie Berlin, Hightech Gruenderfonds II, and KfW. The company, a spin-off from the Max Delbrueck Center for Molecular Medicine, is developing oral small molecules for cardiovascular disease, initially focusing on atrial fibrillation.